Harnessing Data Science Insights to Drive OSD Innovation

Oral solid dosage (OSD) formats offer convenient administration as well as accurate and uniform dosing, which has contributed to their continued popularity and their status as the most globally used drug form [1]. The demand for OSD drugs is still rising, with various new formulation techniques being explored. Recently, data science capabilities have helped to enable the administration of biologics as OSD [2].

Data science facilitates the extraction of meaningful insights from vast datasets. It has been aiding drug development by simplifying integral processes, such as tech transfer or adaptation to different equipment and scales.

As demand for OSD grows, data science is increasingly used to address the issues facing developers and manufacturers throughout product development. These challenges include navigating cost pressures and demands to reduce timelines, as well as the inherent scientific obstacles encountered in manufacturing, such as:

  • Managing drug instability
  • Addressing absorption issues
  • Ensuring consistent drug delivery
  • Navigating regulatory requirements

Poised to continue influencing the entire spectrum of drug production activities, data science is set to be used for in silico models to support product development and optimisation of engineering-driven facility planning, offering a holistic perspective throughout drug quality assurance. These data insights will reduce deviations while fine-tuning planned processes and will expedite the OSD trajectory from initial development to commercialisation.


1. https://www.mantellassociates.com/blog/2021/06/oral-solid-dosage-forms-and-why-they-dominate-the-market?source=google.com
2. https://www.europeanpharmaceuticalreview.com/news/174977/osd-contract-manufacturing-market-valued-at-54-7-billion-by-2030/

Author Image
Uwe Hanenberg

Head of Product Development, Oral Solid Dose, Recipharm

Company Logo